2-Chloropyridine → (R)-tert-butyl 3-(pyridin-2-ylamino)piperidine-1-carboxylate

HRID 601

Reaktionsgleichung

Reaktionsgleichung von HRID 601
CC(C)(C)OC(=O)N1CCC[C@@H](N)C1.Clc1ccccn1>CC(C)(C)[O-].Cc1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.[Na+].[Pd].[Pd].c1ccc(P(c2ccccc2)c2ccc3ccccc3c2-c2c(P(c3ccccc3)c3ccccc3)ccc3ccccc23)cc1>CC(C)(C)OC(=O)N1CCC[C@@H](Nc2ccccn2)C1

Komponenten

7

Reaktionsbedingungen

Temperatur
110 °C

Versuchsvorschrift

Vial 1) Pd2(dba)3 (0.018 g, 0.02 mmol) and BINAP (0.024 g, 0.04 mmol) were mixed in toluene (1mL) under N2 and stirred at rt for 5min. Vial 2) sodium tert-butoxide (0.999 g, 10.08 mmol), tert-butyl (R)-3-aminopiperidine-1-carboxylate (1.249 g, 6.05 mmol) and 2-chloropyridine (0.477 mL, 5.04 mmol) were mixed in toluene (6mL) under N2. Added the catalyst solution from vial 1. The mixture was heated at 110°C in an oil-bath. LCMS (3h): product, no SM left. The reaction was cooled to rt and the solvent was evaporated. Added EtOAc, washed with water. Purified by column chromatography (using SP4 TM HPFC system, KP-Sil (50g) column, A=heptane, B=EtOAc/2M NH3 in MeOH (9/1), 27mL/fr, (0% B 2CV, 0-30% B 10CV, 30% B 2CV)) to yield tert-butyl (R)-3-(pyridin-2-ylamino)piperidine-1-carboxylate (1.306 g, 93 %) as yellow solid. [M+H]+ 278. 1H NMR (400 MHz, CDCl3) d 1.42 (s, 9H), 1.51 - 1.64 (m, 2H), 1.68 - 1.8 (m, 1H), 1.93 - 2.05 (m, 1H), 2.81 - 3.36 (m, 2H), 3.45 - 4.16 (m, 3H), 4.50 (d, 1H), 6.42 (d, 1H), 6.5 - 6.62 (m, 1H), 7.36 - 7.45 (m, 1H), 8.02 - 8.13 (m, 1H). Expected Number of Hs: 23 Assigned Hs: 23.

Quellen und Nachweise

ORD-Eintrag
ord-3016ae12f45142f49e43a15eaa293eb1
Quelldatensatz
750 AstraZeneca ELN dataset
Originallink
Quelle ansehen

Verknüpfte Notizen

Wird geladen…